Eli Lilly | LLY

Stock Price
729.01
Daily Change
-8.11 -1.11%
Monthly
-5.92%
Yearly
93.75%
Q2 Forecast
763.10
Peers Price Chg Day Year Date
ABBV AbbVie 167.20 -0.81 -0.48% 3.34% Apr/25
ABT Abbott 106.90 -0.06 -0.06% -1.70% Apr/25
ALKS ALKERMES 24.44 0.37 1.52% -13.90% Apr/25
AMGN Amgen 269.42 -3.72 -1.36% 12.82% Apr/25
AZN AstraZeneca 11,974.00 -52.00 -0.43% 1.51% Apr/26
BAX Baxter International 40.25 -0.73 -1.78% -12.65% Apr/25
BIIB Biogen 202.49 0.36 0.18% -29.70% Apr/25
BMY Bristol-Myers Squibb 44.70 -4.16 -8.51% -34.28% Apr/25
CTLT Catalent 55.80 -0.14 -0.25% 31.73% Apr/25
GILD Gilead Sciences 65.07 -1.83 -2.73% -22.30% Apr/25
GSK GlaxoSmithKline 1,635.50 -5.00 -0.30% 13.81% Apr/26
GSK Glaxosmithkline 40.91 0.05 0.12% 13.86% Apr/25
JNJ J&J 146.84 -1.73 -1.16% -9.70% Apr/25
LLY Eli Lilly 729.01 -8.11 -1.11% 93.75% Apr/25
MDT Medtronic 79.06 -1.21 -1.50% -12.13% Apr/25
MRK Merck 130.49 3.59 2.83% 15.04% Apr/25
NBIX Neurocrine Biosciences 137.73 -1.24 -0.89% 34.08% Apr/25
NOVN Novartis 89.36 -0.64 -0.71% -2.18% Apr/26
NVS Novartis 99.12 0.74 0.75% -3.34% Apr/25
PBH Prestige Brands 70.14 0.01 0.01% 14.81% Apr/25
PFE Pfizer 25.26 -0.97 -3.69% -34.61% Apr/25
PRGO Perrigo 31.26 0.03 0.10% -13.28% Apr/25
RDY Drreddys Laboratories 74.02 3.10 4.37% 24.47% Apr/25
REGN Regeneron Pharmaceuticals 906.54 -16.99 -1.87% 16.52% Apr/25
ROG Roche Holding 219.45 0.65 0.30% -20.55% Apr/26
SAN Sanofi 89.74 -1.88 -2.05% -11.86% Apr/26
SNY Sanofi 49.33 2.77 5.95% -12.26% Apr/25
UTHR United Therapeutics 235.98 -1.02 -0.43% 4.48% Apr/25
ZTS Zoetis 153.44 2.51 1.66% -11.28% Apr/25

Indexes Price Day Year Date
SPX US500 5082 -23.21 -0.46% 22.89% Apr/26

Eli Lilly traded at $729.01 this Thursday April 25th, decreasing $8.11 or 1.11 percent since the previous trading session. Looking back, over the last four weeks, Eli Lilly lost 5.92 percent. Over the last 12 months, its price rose by 93.75 percent. Looking ahead, we forecast Eli Lilly to be priced at 763.10 by the end of this quarter and at 720.21 in one year, according to Trading Economics global macro models projections and analysts expectations.

Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products include Cymbalta, Emgality, Reyvow, Strattera and Zyprexa. Its Oncology products include Alimta, Cyramza, Erbitux and Verzenio. Other product includes Cialis, for the tratment of erectile dysfunction and benign prostatic hyperplasia. The Company manufacture and distribute its products through facilities in the United States, Puerto Rico, and 8 other countries. Its products are sold in approximately 120 countries.